QD Clinic: Gout: Is it the Journey or the Destination? Dr. Arthur Kavanaugh discusses a gout patient whose frequent flares improved after lifestyle changes, despite medication not being enough on its own. https://t.co/frf4O87L0I https://t.co/cjtiYY9Ayt

Predicting and Managing Gout Flares in Hospitalized Patients Dr. Kanon Jatuworapruk, Bangkok, discusses predicting and managing gout flares in hospitalized patients as part of RheumNow's "Gout: More than Flares" campaign in July 2026. https://t.co/wrLbjsayrI https://t.co/eWmRqPNWsJ

51 yoM w/ 2 yrs of FUO, unintentional 32-kg wt loss, LN, diffuse myalgias, but no GI Sxs or arthralgia. Neg MRIs, CT, PET scan, EGD, colonoscopy. Abnl labs: CRP 173 mg/L, ESR 46, anemia & ^ WBC. Cell-free DNA next-generation sequencing dx Tropheryma whipplei, & Whipple disease https://t.co/nJLa4l7Ers

Genetic study of 16 pts w/ Allopurinol-induced severe cutaneous adverse Rxn (SJS/TEN) shows 2 class I alleles to be associated: HLA-B*58:01 (OR, 28.0 [95% CI, 8.6-100.6]) and HLA-A*34:02 (OR, 20.6 [95% CI, 3.3-131.1]). Both explain 80% risk in US pts https://t.co/OxDXuWCbup https://t.co/oky61JImQV

Psoriatic Arthritis: EULAR 2026 Recap https://t.co/tBMu4CEn0o https://t.co/iztShOHxOf

Seronegative RA Disease Activity (7.17.2026) Dr. Jack Cush reviews the news, journal articles and Gout features from this past week on RheumNow and check your knowledge in this week's RheumIQ quiz! https://t.co/e0u9qwtHVi https://t.co/oav00L7Lzw

ACR: Medicare Cuts for Physicians Highlight Need for Reform The ACR was disappointed that the proposed MPFS from the CMS once again included a serious cut to the conversion factor. The -1.68% cut would lower reimbursement to physicians providing care to Medicare beneficiaries https://t.co/PmAmFPnw6R

The Marriage between Gout and the Kidney While the link between uric acid and gout was first described by Alfred Baring Garrod in the 1800s, the proof that uric acid might actually be the cause had to await the self-experimentation of two rheumatologists from the University of https://t.co/AWZbjaUtdu

From 2015-2024, 148 inflam arthritis pts (43 SpA, 35 PsA, 50 RA) w/ a prior cancer were followed 58.1 mos. 24 (19%) had CA recurrence/progression. Post-CA exposure to b/ts-DMARDs did not incr. recurrence risk after adjusting for age & comorbidity burden. https://t.co/MHKIqwyjNN https://t.co/uhOdq1cCPW

SGLT2i use in gout reduces use of gout meds. Study of 26,739 gout pts w/ NIDDM (mean 66 yrs), 67% w/ polypharmacy. SGLT2i (vs DPP-4i) user had less Allopurinol starts (HR 0.62;0.52–0.73), also lower use of steroids (,78), NSAID (.85), colchicine (.87) & diuretics (.87) https://t.co/1dW27YzSvg